Aligos therapeutics presents positive data at the liver meeting (tlm) 2024

South san francisco, calif., nov. 19, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the american association for the study of liver disease's (aasld) the liver meeting (tlm) 2024, being held november 15 – 19, 2024 in san diego, ca.
ALGS Ratings Summary
ALGS Quant Ranking